- Soleno Therapeutics shares (NASDAQ:SLNO) rallied after Neurocrine Biosciences agreed to acquire the company for US$53 per share in cash, valuing the deal at about US$2.9 billion
- Neurocrine said the acquisition expands its medicines portfolio and strengthens its position in endocrinology and rare diseases, adding Soleno’s approved treatment for Prader–Willi syndrome
- The deal, funded primarily with cash, reflects investor optimism about Soleno’s rare‑disease asset, while highlighting Neurocrine’s strategy to diversify beyond its core neuroscience focus
- Soleno Therapeutics stock (NASDAQ:SLNO) opened trading at US$52.31
Shares of Soleno Therapeutics (NASDAQ:SLNO) surged nearly 40 per cent to kick off the trading week after Neurocrine Biosciences (NASDAQ:NBIX) said it has agreed to acquire the rare‑disease drugmaker for US$53 per share in cash, a deal that values Soleno at approximately US$2.9 billion.
The offer represents a premium of roughly 34 per cent to Soleno’s previous closing price, reflecting the strategic value Neurocrine sees in Soleno’s approved treatment and its position in a high‑need rare disease market. Soleno stock was briefly halted following the announcement amid heavy trading volumes.
Neurocrine said the acquisition will help broaden its medicine portfolio beyond neuroscience and deepen its presence in endocrinology and rare disease, areas that management considers key growth drivers for the company.
Strategic rationale
Soleno’s primary asset is Vykat XR, a once‑daily oral therapy approved by the U.S. Food and Drug Administration in March 2025 for the treatment of hyperphagia associated with Prader–Willi syndrome (PWS), a rare genetic disorder marked by chronic, life‑threatening hunger. Vykat XR is currently the only FDA‑approved drug for that indication.
For Neurocrine, whose commercial products have historically been concentrated in neurology, the acquisition marks a meaningful step into metabolic and endocrine disorders. The company said Soleno’s therapy complements its existing portfolio and strengthens its long‑term competitive position in specialty medicine markets characterized by high unmet medical need and limited competition.
Analysts broadly viewed the deal as a faster and less risky way for Neurocrine to expand into metabolic disease than developing internal obesity or endocrine candidates from early‑stage research.
Financial and market impact
According to company statements, Neurocrine plans to fund the transaction with cash on hand, supplemented by a modest amount of pre‑payable debt. The deal has been approved by both companies’ boards and is expected to close within approximately 90 days, subject to customary regulatory and closing conditions.
While Soleno shares surged sharply, Neurocrine’s stock edged lower following the announcement, reflecting investor caution around acquisition execution risk and near‑term financial impact — a common reaction when large cash deals are announced in the biotech sector.
Soleno reported rapid early uptake of Vykat XR following its launch, and analysts cited the drug’s long intellectual‑property runway as a key factor underpinning the acquisition valuation.
Broader context
The transaction continues a broader trend of large pharmaceutical companies acquiring late‑stage or commercial rare‑disease assets, as pricing pressure and patent expirations challenge traditional blockbuster drug models. Rare‑disease drugs often support durable revenue streams due to limited competition and strong reimbursement frameworks.
For Soleno investors, the deal crystallizes significant value following the successful regulatory approval of its lead product. For Neurocrine shareholders, the acquisition represents a strategic bet on portfolio diversification and long‑term growth beyond its core neuroscience franchise.
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablet for the treatment of Prader-Willi Syndrome.
Soleno Therapeutics stock (NASDAQ:SLNO) opened trading more than 30 per cent higher at US$52.31 and though it was up more than 70 per cent last week, it is down more than 22 per cent since this time last year.
Neurocrine Biosciences Inc. stock (NASDAQ:NBIX) was down more than 3 per cent at market open at US$130.93.
Join the discussion: Find out what everybody’s saying about this healthcare stock on the Soleno Therapeutics Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.